Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
December 12, 2005
- Supply of All Specifications "Hurdle That Must Be Overcome": JGPMA
December 12, 2005
- New Medical Materials Should Be Listed 4 Times a Year: Device Industry
December 5, 2005
- Committee Approves Basic Proposal for Next Revision of Med. Fees
December 5, 2005
- 58% of Pharmacists Have Been Asked to Dispense Generics: Survey
December 5, 2005
- Approval of 3 New Products Recommended
December 5, 2005
- Only Stably Supplied Generics Should Be Covered by Insurance: Mr Futagawa
December 5, 2005
- Social Security Spending Needs Further Cuts
December 5, 2005
- Economic Effects of Generics Depend on Their Efficacy: Research Result
December 5, 2005
- MOF's Council Proposes Considerable Cut in Medical Fees
December 5, 2005
- Generic Drug Sales Outpacing the Market: Fuji-keizai
December 5, 2005
- AstraZeneca to Boost Market Share Through 1,700 MR Force: Dr Kato
December 5, 2005
- Generic Substitution Will Become Easier: Mr Yoshida of Towa
December 5, 2005
- BUSINESS NEWS IN BRIEF
December 5, 2005
- Towa: Sales Down 1.1% Due to Poor Sales of New Products
December 5, 2005
- Korosho Presents NHI Pricing Reform Proposal at Chuikyo's Expert Subcommittee Meeting
December 5, 2005
- Taiyo Pharm. Ind. to Take Clear Lead in GE Drug Industry: Mr Aratani
December 5, 2005
- Pressure Increases toward Once-yearly NHI Price Revision
December 5, 2005
- Toho: Profits Decline 39.3% Despite 24.6% Growth in Sales
December 5, 2005
- PhRMA Disappointed by Chuikyo's NHI Pricing Reform Proposal
December 5, 2005
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…